TYRUKO DIN 02561123
Status: Approved
Holder: POLPHARMA BIOLOGICS S.A.
Health Canada record
| Active ingredient(s) | NATALIZUMAB 300 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L04AG03 NATALIZUMAB |
|---|
| Original market date | |
|---|
| Current status date | 24-Sep-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Polpharma Biologics S.A. — licence , not currently licensed, last inspection rating C (2025-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NATALIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02286386 | TYSABRI | BIOGEN CANADA INC | Solution | NATALIZUMAB 300 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36056 | 2025-09-24 | New Drug Submission (NDS) | |
Request a quote for TYRUKO
How to read a Canadian DIN record